Our findings underscore the significance of pretreatment systemic inflammation (e.g. serum TNF-α levels), T-naive product phenotype, TMTV, tumor IFN signaling, and posttreatment CAR T cell expansion as independent prognostic factors, positively or negatively (covariate specific) associated with efficacy, in patients with r/r FL treated with axi-cel (Figure 9A). Here, TNF is linked to neoplasm.